Hormone Therapy for Lung Cancer Bronx NY

Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

Local Companies

Sound Shore Medical Center
914-632-5000
16 Guion Place
New Rochelle, NY
Metropolitan Hospital Center
212-423-6262
1901 First Avenue
New York, NY
Coler-Goldwater Spec Hospital
212-318-8000
One Main Street
New York, NY
Libertyhealth-Greenville Hosp
201-547-6100
1825 John F Kennedy Boulevard
Jersey City, NJ
Brookdale Hospital Medical Ctr
718-240-5000
Linden Blvd At Brookdale Plaza
Brooklyn, NY
North Shore Univ Hospital
516-496-6400
221 Jericho Turnpike
Syosset, NY
Veterans Affairs Med Center
718-584-9000
130 West Kingsbridge Road
Bronx, NY
Gracie Square Hospital
212-988-4400
420 East 76th Street
New York, NY
Libertyhealth-Jersey City Ctr
201-915-2000
355 Grand Street
Jersey City, NJ
Va New Jersey Hlth Care Syst
973-676-1000
385 Tremont Avenue
East Orange, NJ
Data Provided by:
  

Provided By:

SATURDAY, Sept. 19 (HealthDay News) -- Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found.

The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

After eight years, 73 women taking the hormone therapy and 40 women in the placebo group had died of lung cancer. That meant, according to the researchers, that women who took the drug were 71 percent more likely to die from the disease.

The study also found that women taking the hormone therapy were 28 percent more likely to be diagnosed with lung cancer, although the study noted that the finding was not statistically significant.

"Treatment with estrogen plus progestin in postmenopausal women ... increased the number of deaths from lung cancer, in particular deaths from non-small-cell lung cancer," concluded Rowan Chlebowski, of the Los Angeles Biomedical Research Institute at Harbour-UCLA Medical Center, and his colleagues.

The researchers urged that the findings "be incorporated into risk-benefit discussions with women considering combined hormone therapy, especially those with a high risk of lung cancer ... such as current smokers or long-term past smokers."

Dr. Apar Kishor Ganti, from the University of Nebraska Medical Center in Omaha, wrote in an accompanying editorial that "because the optimum safe duration of hormone-replacement therapy in terms of lung cancer survival is unclear, such therapy should probably be avoided in women at a high risk of developing lung cancer, especially those with a history of smoking."

In fact, Ganti questioned whether hormone therapy should be used at all.

"These results, along with the findings showing no protection against coronary heart disease, seriously question whether hormone-replacement therapy has any role in medicine today," he wrote. "It is difficult to presume that the benefits of routine use of such therapy for menopausal symptoms outweigh the increased risks of mortality, especially in the absence of improvement in the quality of life."

The study, which appears online and in an upcoming print issue of The Lancet, was released Sept. 19 to coincide with the European Cancer Organization meeting.

More information

The U.S. National Institute on Aging has more on hormones and menopause.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Drug Combo Proves Powerful Against Lung Cancer Bronx NY
A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.
- Hormone Therapy for Prostate Cancer Bronx NY
- Hormone Therapy Bronx NY
- Delayed Prostate Cancer Therapy Bronx NY
- Menopausal Hormone Therapy Bronx NY
- Head and Neck Cancer Treatment Bronx NY
- Hormone Therapy for Early Prostate Cancer Bronx NY
- Breast Cancer Treatment Bronx NY
- Hormone Therapy for Breast Cancer Bronx NY